{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:37:58Z","timestamp":1761323878143,"version":"build-2065373602"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-025-00832-w","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:33:31Z","timestamp":1761323611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic survey"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5954-1296","authenticated-orcid":false,"given":"Masahiro","family":"Takada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehira","family":"Saji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-9377","authenticated-orcid":false,"given":"Takayuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-0278","authenticated-orcid":false,"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Sugie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1488-9958","authenticated-orcid":false,"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66, 15\u201323 (2022).","journal-title":"Breast"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin, J. L. et al. Analysis of breast cancer mortality in the US-1975 to 2019. JAMA 331, 233\u2013241 (2024).","journal-title":"JAMA"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni, M. et al. annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J. Clin. Oncol. 34, 927\u2013935 (2016).","journal-title":"J. Clin. Oncol."},{"key":"832_CR4","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836\u20131846 (2017).","journal-title":"N. Engl. J. Med."},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(20)30534-9","volume":"22","author":"M Toi","year":"2021","unstructured":"Toi, M. et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22, 74\u201384 (2021).","journal-title":"Lancet Oncol."},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-023-07099-4","volume":"202","author":"M Takada","year":"2023","unstructured":"Takada, M. et al. A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer. Breast Cancer Res. Treat. 202, 485\u2013496 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein, H. J. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J. Clin. Oncol. 37, 423\u2013438 (2019).","journal-title":"J. Clin. Oncol."},{"key":"832_CR8","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. 38, 3987\u20133998 (2020).","journal-title":"J. Clin. Oncol."},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon, D. et al. Ribociclib plus endocrine therapy in early breast cancer. N. Engl. J. Med. 390, 1080\u20131091 (2024).","journal-title":"N. Engl. J. Med."},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1634\/theoncologist.2019-0103","volume":"24","author":"MV Dieci","year":"2019","unstructured":"Dieci, M. V. et al. Impact of 21-gene breast cancer assay on treatment decision for patients with T1-T3, N0-N1, estrogen receptor-positive\/human epidermal growth receptor 2-negative breast cancer: final results of the prospective multicenter ROXANE study. Oncologist 24, 1424\u20131431 (2019).","journal-title":"Oncologist"},{"key":"832_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano, G. et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann. Oncol. 34, 970\u2013986 (2023).","journal-title":"Ann. Oncol."},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi, P. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarche overall survival interim analysis, including 5-year efficacy outcomes. J. Clin. Oncol. 42, 987\u2013993 (2024).","journal-title":"J. Clin. Oncol."},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J. Clin. Oncol. 41, 1376\u20131382 (2023).","journal-title":"J. Clin. Oncol."},{"key":"832_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett, M. et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28, 509\u2013518 (2010).","journal-title":"J. Clin. Oncol."},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341\u20131352 (2015).","journal-title":"Lancet"},{"key":"832_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/jamaoncol.2021.1854","volume":"7","author":"TWP Friedl","year":"2021","unstructured":"Friedl, T. W. P. et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial. JAMA Oncol. 7, 1149\u20131157 (2021).","journal-title":"JAMA Oncol."},{"key":"832_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.103604","volume":"73","author":"M Ito","year":"2024","unstructured":"Ito, M. et al. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy. Breast 73, 103604 (2024).","journal-title":"Breast"}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00832-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00832-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00832-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T16:33:32Z","timestamp":1761323612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-025-00832-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1038\/s41523-025-00832-w","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.Ta. received research grants from Yakult, Guardant Health Japan, and Medbis and lecture fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Chugai, Taiho, MSD, Eisai, Exact Science, Kyowa Kirin, and Pfizer. M.Ta. is also a member of the board of directors of the Japan Breast Cancer Research Group Association (JBCRG) and the Kyoto Breast Cancer Research Network (KBCRN). S.S. received research grants from Taiho, Eisai, Chugai, Takeda, MSD, Astra Zeneca, Daiichi Sankyo, Gilead, Eli Lilly, and Sanofi, lecture fees from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, Astra Zeneca, Pfizer, Taiho, Ono, Nipponkayaku, Gilead, Exact Sciences, and has an advisory role for Chugai\/Roche, Astra Zeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD. T.U. received lecture fees from AstraZeneca, Chugai, Eisai, and Novartis and a research grant from Eli Lilly. N.M. received research grants from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, MSD, Novartis, Ono-Pharma, and Pfizer; and lecture fees from AstraZeneca, Chugai, Daiichi Sankyo, Eli Lilly, and Pfizer. N.M. is also a member of the board of directors of the Japan Breast Cancer Society (JBCS), the Japan Society of Clinical Oncology (JSCO), and JBCRG. H.Is. received research grants from Eisai, Daiichi Sankyo, Chugai, Takeda, Astra Zeneca, MSD, and Ono and lecture fees from Eisai, Chugai, Kyowa Kirin, Daiichi Sankyo, Taiho, Astra Zeneca, MSD, and Mitsubishi Tanabe Pharma. S.I. received research grants from Chugai, Taiho, and Eisai. S.O. received lecture fees from Kyowa Kirin, Eli Lilly, MSD, Chugai, and Nippon Kayaku. H.Iw. received consulting fees from Daichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, and Gilead, and lecture fees from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. K.A. received lecture fees from Chugai, Eisai, AstraZeneca, Taiho, Novartis, Daiichi Sankyo, Mochida, Ono, Pfizer, Eli Lilly, Astellas, Nestle Japan, and Gilead Science and research grants from Chugai, Eisai, and Takeda. M.To. received research grants from Chugai, Takeda, Pfizer, Taiho, JBCRG, KBCRN, Eisai, Eli Lilly, Daiichi Sankyo, Astra Zeneca, Astellas, Shimadzu, Yakult, Nippon Kayaku, AFI technology, Luxonus, Shionogi, GL Science, and Sanwa Shurui, lecture fees from Chugai, Takeda, Pfizer, Kyowa Kirin, Taiho, Eisai, Daiichi Sankyo, Astra Zeneca, Eli Lilly, MSD, Exact Science, Novartis, Shimadzu, Yakult, Nippon Kayaku, Devicore Medical Japan, and Sysmex, and advisory fees from Daiichi Sankyo, Eli Lilly, BMS, Bertis, Terumo, and Kansai Medical Net. M.To. is also a member of the board of directors of JBCRG, KBCRN, JBCS, and Organisation for Oncology and Translational Research. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}